153994-69-5

Basic information

• Product Name: 3-(1-Amino-ethyl)-benzoic acid methyl ester
• Synonyms: 3-(1-Amino-ethyl)-benzoic acid methyl ester;METHYL 3-(1-AMINOETHYL)BENZOATE
• CAS NO: 153994-69-5
• Molecular Formula: C₁₀H₁₃NO₂
• Molecular Weight: 179.21572
• Mol File: 153994-69-5.mol

Chemical Properties

• Boiling Point: 278.1±23.0 °C(Predicted)
• Appearance: /
• Density: 1.089±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 8.78±0.10(Predicted)
• CAS DataBase Reference: 3-(1-Amino-ethyl)-benzoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(1-Amino-ethyl)-benzoic acid methyl ester(153994-69-5)
• EPA Substance Registry System: 3-(1-Amino-ethyl)-benzoic acid methyl ester(153994-69-5)

Safety Data

• Hazardous Substances Data: 153994-69-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-(1-Amino-ethyl)-benzoic acid methyl ester is used as a starting material for the synthesis of pharmaceuticals due to its versatile chemical structure and functional groups that can be further modified to create a variety of medicinal compounds.
Used in Organic Synthesis:
In the field of organic synthesis, 3-(1-Amino-ethyl)-benzoic acid methyl ester serves as a key intermediate, facilitating the creation of a wide range of organic compounds for various applications, including but not limited to, the development of new drugs, agrochemicals, and specialty chemicals.
Used in Drug Development Research:
3-(1-Amino-ethyl)-benzoic acid methyl ester is utilized in drug development research for its potential to be transformed into therapeutic agents with antioxidant and anti-inflammatory properties, making it a candidate for treating various medical conditions that involve oxidative stress and inflammation.

Upstream product

• 1027256-76-3 methyl 3-{1-[(tert-butoxycarbonyl)amino]ethyl}benzoate 
• 878804-98-9 methyl 3-(1-azidoethyl)benzoate 

Downstream Products

• 1027256-78-5 methyl 3-{1-[(6-chloropyrazin-2-yl)amino]ethyl}benzoate 

Relevant articles and documents

INHIBITORS OF KINASE ACTIVITY

The present invention relates to pyridines or pyrazines that inhibit kinases. In particular the compounds of the invention inhibit members of the class III PTK receptor family such as FMS (CSF-IR), c-KIT, PDGFRβ, PDGFRα or FLT3 and KDR, SRC, EphA2, EphA3, EphA8, FLTl, FLT4, HCK, LCK, PTK5 (FRK), SYK, DDRl and DDR2 and RET. The compounds of the invention are useful in the treatment of kinase associated diseases such as immunological and inflammatory diseases; hyperproliferative diseases including cancer and diseases involving neo-angiogenesis; renal and kidney diseases; bone remodeling diseases; metabolic diseases; and vascular diseases.

NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES

The present invention relates to a compound represented by Formula [I] or a pharmaceutically acceptable salt or ester thereof: wherein: X1, X2, X3, and X4, which may be identical or different, are each C or N, provided that none to two of X1, X2, X3, and X4 is/are N; Y is CH or N; R1, R1', R2, R2', R3, R3', R4, and R4', which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R5 is a hydrogen atom or a methyl group; R6 and R7, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R8 and R8', which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R9 is an aryl group or a heteroaryl group which may be substituted; and n is an integer from 1 to 3, and a PLK1 inhibitor or an anticancer agent containing the same.